Enanta Pharmaceuticals Stock Buy Hold or Sell Recommendation
| ENTA Stock | USD 9.34 0.03 0.32% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Enanta Pharmaceuticals is 'Hold'. Macroaxis provides Enanta Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ENTA positions.
Check out Enanta Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide. In addition, we conduct extensive research on individual companies such as Enanta and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Enanta |
Execute Enanta Pharmaceuticals Buy or Sell Advice
The Enanta recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Enanta Pharmaceuticals. Macroaxis does not own or have any residual interests in Enanta Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Enanta Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Enanta Pharmaceuticals Trading Alerts and Improvement Suggestions
| Enanta Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 79.2 M. Net Loss for the year was (133.82 M) with profit before overhead, payroll, taxes, and interest of 86.16 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (103.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enanta Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Acquisition by Peterson Kristine of 10800 shares of Enanta Pharmaceuticals at 47.72 subject to Rule 16b-3 |
Enanta Pharmaceuticals Returns Distribution Density
The distribution of Enanta Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Enanta Pharmaceuticals' future price movements. The chart of the probability distribution of Enanta Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Enanta Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Enanta Pharmaceuticals returns is essential to provide solid investment advice for Enanta Pharmaceuticals.
| Mean Return | -0.41 | Value At Risk | -4.71 | Potential Upside | 3.86 | Standard Deviation | 2.58 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Enanta Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Enanta Stock Institutional Investors
| Shares | Northern Trust Corp | 2024-09-30 | 536.7 K | D. E. Shaw & Co Lp | 2024-06-30 | 534.2 K | Renaissance Technologies Corp | 2024-09-30 | 524.9 K | Boothbay Fund Management, Llc | 2024-06-30 | 483.3 K | Citadel Advisors Llc | 2024-06-30 | 465.4 K | Geode Capital Management, Llc | 2024-06-30 | 462.8 K | State Street Corp | 2024-06-30 | 422.8 K | Tang Capital Management Llc | 2024-06-30 | 300 K | Two Sigma Advisers, Llc | 2024-06-30 | 232.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.9 M | Farallon Capital Management, L.l.c. | 2024-06-30 | 2.1 M |
Enanta Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 35.9M | (29.9M) | (9.9M) | 41.4M | 47.6M | 50.0M | |
| Free Cash Flow | 5.6M | (70.7M) | (86.9M) | (112.2M) | (101.0M) | (95.9M) | |
| Depreciation | 3.6M | 3.3M | 3.0M | 2.4M | 2.7M | 1.9M | |
| Other Non Cash Items | (3.5M) | (2.0M) | 242K | 2.6M | 2.3M | 2.5M | |
| Capital Expenditures | 1.4M | 750K | 2.1M | 9.1M | 10.4M | 10.9M | |
| Net Income | (36.2M) | (79.0M) | (121.8M) | (133.8M) | (120.4M) | (114.4M) | |
| End Period Cash Flow | 87.7M | 57.8M | 48.0M | 89.4M | 102.8M | 107.9M | |
| Investments | 21.3M | 37.7M | 57.0M | (53.6M) | (61.6M) | (58.5M) | |
| Change To Netincome | 10.3M | 26.4M | 19.4M | 27.2M | 31.3M | 32.9M |
Enanta Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Enanta Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Enanta Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Enanta stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.53 | |
β | Beta against Dow Jones | 0.87 | |
σ | Overall volatility | 2.53 | |
Ir | Information ratio | -0.21 |
Enanta Pharmaceuticals Volatility Alert
Enanta Pharmaceuticals exhibits very low volatility with skewness of 0.19 and kurtosis of -0.56. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enanta Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enanta Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Enanta Pharmaceuticals Fundamentals Vs Peers
Comparing Enanta Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Enanta Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Enanta Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Enanta Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Enanta Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Enanta Pharmaceuticals to competition |
| Fundamentals | Enanta Pharmaceuticals | Peer Average |
| Return On Equity | -0.6 | -0.31 |
| Return On Asset | -0.17 | -0.14 |
| Profit Margin | (1.60) % | (1.27) % |
| Operating Margin | (1.35) % | (5.51) % |
| Current Valuation | 18.38 M | 16.62 B |
| Shares Outstanding | 21.19 M | 571.82 M |
| Shares Owned By Insiders | 6.00 % | 10.09 % |
| Shares Owned By Institutions | 94.00 % | 39.21 % |
| Number Of Shares Shorted | 3.44 M | 4.71 M |
| Price To Earning | 366.13 X | 28.72 X |
| Price To Book | 1.32 X | 9.51 X |
| Price To Sales | 2.75 X | 11.42 X |
| Revenue | 79.2 M | 9.43 B |
| Gross Profit | 86.16 M | 27.38 B |
| EBITDA | (123.48 M) | 3.9 B |
| Net Income | (133.82 M) | 570.98 M |
| Cash And Equivalents | 253.29 M | 2.7 B |
| Cash Per Share | 12.22 X | 5.01 X |
| Total Debt | 26.51 M | 5.32 B |
| Debt To Equity | 0.08 % | 48.70 % |
| Current Ratio | 13.59 X | 2.16 X |
| Book Value Per Share | 7.03 X | 1.93 K |
| Cash Flow From Operations | (103.15 M) | 971.22 M |
| Short Ratio | 20.91 X | 4.00 X |
| Earnings Per Share | (5.45) X | 3.12 X |
| Target Price | 19.63 | |
| Number Of Employees | 145 | 18.84 K |
| Beta | 0.57 | -0.15 |
| Market Capitalization | 197.9 M | 19.03 B |
| Total Asset | 462.27 M | 29.47 B |
| Retained Earnings | (207 M) | 9.33 B |
| Working Capital | 360 M | 1.48 B |
| Current Asset | 241.79 M | 9.34 B |
Note: Acquisition by Gardiner Nathaniel S. of 9250 shares of Enanta Pharmaceuticals subject to Rule 16b-3 [view details]
Enanta Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Enanta . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Enanta Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Enanta Pharmaceuticals? Buying financial instruments such as Enanta Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Enanta Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Education Thematic Idea Now
Education
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Enanta Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (5.45) | Revenue Per Share 3.407 | Quarterly Revenue Growth (0.05) | Return On Assets (0.17) |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.